molecules of the month


oral selective DNA-PK kinase inhibitor

synergy with radiotherapy in model

from library screen

Journal of Medicinal Chemistry

Bayer AG, Berlin, Germany

1 min read

The Bayer DNA-PK inhibitor, BAY-8400, is an orally active and selective DNA-PK kinase inhibitor that synergistically enhances the efficacy of radiotherapeutics in xenograft models. The program started with a campaign to identify ATR inhibitors, which resulted in hits against ATR, ATM, and DNA-PK, all of which are of interest due to their roles in DNA damage repair. It will be interesting to watch this active space to see whether ATR, ATM, or DNA-PK inhibition can improve therapeutic indexes or efficacy of various DNA-damaging treatments clinically.

request a trial

You don’t have time to read everything, but you can’t afford to fall behind.

Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.

Get ahead now by requesting a trial.

already a member? log in: